Draft, not yet released. In stewardship review. Not indexed until the first approved release.

Design capability outpaces screening and oversight

A conditional statement under stated assumptions, never a prediction.

2 min read0 figures0 tables2 notesNR-XTECH-SYNBIO-GLOBAL-2026-BASELINE

Contents
  1. ·Edition home
  2. ·Executive summary
  3. 1Synthetic biology is a build capability and a governance test
  4. 2Key findings
  5. 3Systems and sectors at baseline
  6. 4Risks and capability
  7. 5Design capability outpaces screening and oversight
    1. 5.1 Assumptions
    2. 5.2 The cascade, step by step
    3. 5.3 The scenario as a table of steps
  8. 6Readings from the other desks
  9. 7The 2027 agenda
  10. 8Systems in depth
  11. AMethodology
  12. BData appendix
  13. CReferences and record
  14. ·Complete edition, for print

5.1Assumptions

Scenario SCN-XT04-DSG-01: what is assumed, and what is held constant.

Baseline
the 2026 reference state in this edition
Drivers
design tools and low-cost DNA improve faster than screening practice and framework text
Analogues
the 2025 screening study and the 2025 executive order1326
Interventions
none modelled: the specification describes the unmitigated case
Run state
narrative specification; quantified run scheduled for 2027

5.2The cascade, step by step

  1. 1

    AIC → BIO

    design tools make novel sequences easier to produce

    2023

  2. 2

    DAT → SEC

    screening tools miss some redesigned sequences

    2025

  3. 3

    GOV → SEC

    framework text is revised while practice differs by provider

    2025

  4. 4

    FIN → INF

    investment concentrates in providers with in-house screening

    2026

  5. 5

    GOV → TRD

    national rules and export controls diverge

    2026

  6. 6

    BIO → HLT

    public trust in engineered products is tested

    2025

5.3The scenario as a table of steps

How the shock in scenario SCN-XT04-DSG-01 would travel through Synthetic Biology and Bioengineering’s coupled systems, step by step, under the assumptions the edition states.

StepWhat happensSource
01 AI compute to biodiversityDesign tools make novel sequences easier to produce. Analogue or source: 2023.Edition XT-04, scenario SCN-XT04-DSG-01, step 1
02 DAT to securityScreening tools miss some redesigned sequences. Analogue or source: 2025.Edition XT-04, scenario SCN-XT04-DSG-01, step 2
03 Governance to securityFramework text is revised while practice differs by provider. Analogue or source: 2025.Edition XT-04, scenario SCN-XT04-DSG-01, step 3
04 Finance to infrastructureInvestment concentrates in providers with in-house screening. Analogue or source: 2026.Edition XT-04, scenario SCN-XT04-DSG-01, step 4
05 Governance to tradeNational rules and export controls diverge. Analogue or source: 2026.Edition XT-04, scenario SCN-XT04-DSG-01, step 5
06 Biodiversity to healthPublic trust in engineered products is tested. Analogue or source: 2025.Edition XT-04, scenario SCN-XT04-DSG-01, step 6

A teaching model of a conditional scenario under the edition’s stated assumptions: not a forecast, not a prediction and not a warning. Sources: Synthetic Biology and Bioengineering 2026, scenario SCN-XT04-DSG-01 (2026); Synthetic Biology and Bioengineering 2026, references (NR-CIT-1) (2026).

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
  2. 26UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.back

Cite this chapter

Valadbaygi, S. (Ed.). (2026). Chapter 5: Design capability outpaces screening and oversight. In Exponential Technology Report 2026: Synthetic Biology and Bioengineering (Baseline Edition 2026, Report No. NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE) [Draft under review]. The Global Centre for Risk and Innovation (GCRI).

Every citation form of the whole report, BibTeX and RIS included, is on the edition home. Cite this report

ReportsContribute

Send evidence or a correction on Synthetic Biology and Bioengineering.

Reports is the Consortium’s quarterly publication, written by six desks. This page sits with the Global Centre for Risk and Innovation (GCRI) Systems Evidence desk. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work. Sent to the wrong desk, it is forwarded, not refused.

GCRI Systems Evidence deskExponential Technology

Never send personal data, sensitive infrastructure detail or anything you have no right to share. A contribution is reviewed before use; sending it confers no authorship or editorial rights, and sponsorship never buys a finding.

CC BY 4.0 Free to read. Text and figures: CC BY 4.0. Data: CC0 1.0. Authors keep copyright. Published by GCRI Canada.

The Global Centre for Risk and Innovation

Science · evidence · measurement

Not for profit

Our articles, maps and twins are free to read and free to republish. Readers and partners keep it that way.

Partner with us

Who funds us

GCRI is a not-for-profit institution. To ask who funds a piece of work, use the funding questions form.

Independence

Editors and the expert reviewers named on each article decide what we publish. Funders and partners do not review or approve articles before publication.

Corrections policy

Licence

Articles: CC BY 4.0. Figures, maps, twins and data: CC BY 4.0. Other uses: ask through the permissions form.

Privacy choices